[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Angers\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":636},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,102,0,25,[9,45,68,98,122,145,170,193,215,238,264,287,312,337,370,394,419,445,473,500,520,542,561,580,612],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100652320","an-evaluation-study-of-nursing-assistants-performance-of-electrocardiograms-in-emergency-departments-as-part-of-a-delegation-of-medical-procedures-100652320",false,"NCT07773636","An Evaluation Study of Nursing Assistants' Performance of Electrocardiograms in Emergency Departments as Part of a Delegation of Medical Procedures","ECGSU1","Inclusion Criteria:\n\n* all major and conscient patient admit in the emergency departement of CHU of Angers\n* indication of ECG aquisition in the emergency room reception under prescription medical and\u002For in context of pre-established protocols\n* patient who has been affiliated or beneficiary from social security system\n* patient deliberate consent\n\nExclusion Criteria:\n\n* people under L1121-5 to L1121\\_8 of french law public heath articles, namely pregnant women, laboring women, nursing women, people deprived of freedom from legal decision, minor, people under legal protection (guardianship)\n* people involved in another interventional study changing standard of care or could influence study evaluation criterias\n* pacemaker carrier\n* unable to free consent\n* medical emergency needing immediate ECG acquisition","ALL","18 Years",{"count":20,"type":21},2450,"ESTIMATED","INTERVENTIONAL",[24],"NA","ECG is a simple diagnosis tool which provide a lot of diagnosis and therapeutic decisions. The last few years, the admission number in french emergency department increases in parallel with the ECG acquisition request. ECG acquisition is often made by a nurse, medical skill legally delegate to nurse since 2002. Outside hospital, since 2022, a ministerial decree has extended ECG acquisition to first-aider. The medical delegation of ECG acquisition to nursing assistant could be a way to give back nursing time and would allow to make ECG faster. ECGSU 1 study investigates if the ECG acquisition by a nursing assistant in emergency room reception, for patients admit in emergency department, is qualitatively performant in compare to qualified workers.\n\nMaterials and Method ECGSU 1 study is a non-inferiority, transversal, monocentric, prospective and open trial. The study compares the suitability ratio for ECG's interpretability criteria of ECG made by nursing assistant and made by care workers in current practices (doctors, medical students, nurses). The ECG's interpretability criteria are defined by actual recommendations. The suitability ratio for ECG's interpretability criteria will be considered as reliable if all the interpretability criteria are fulfilled for ECG examination. This examination will be conducted by a blind adjudication committee. 2450 patients will be recruited in 24 months in the emergency department of the CHU of Angers.",[27],"ECG",[29,30,31,32],"nursing assistant","ECG interpretability criteria","act delegation","emergency department","NOT_YET_RECRUITING","2026-08-14",{"date":36,"type":37},"2026-08-19","ACTUAL",{"date":39,"type":21},"2026-10-24",{"date":41,"type":21},"2028-10-23",{"name":43,"class":44},"University Hospital, Angers","OTHER_GOV",{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100652115","study-evaluating-multifaceted-support-for-the-implementation-of-recommendations-for-the-prevention-and-management-of-anemia-in-intensive-care-units-100652115","NCT07771192","Study Evaluating Multifaceted Support for the Implementation of Recommendations for the Prevention and Management of Anemia in Intensive Care Units","STOP-A _ Multicenter, Prospective, Randomized, Stepped-wedge Study Evaluating Multifaceted Support for the Implementation of Recommendations for the Prevention and Management of Anemia in Intensive Care Units","STOP-A","Inclusion Criteria:\n\n* Length of stay in intensive care is ≥ 2 days\n* The patient has at least one organ failure lasting 24 hours or more (catecholamine infusion and\u002For mechanical ventilation (invasive or NIV \\> 6 hours\u002Fday))\n* No objection to data collection (patient or relative)\n\nExclusion Criteria:\n\n* Terminally ill patient with limited active treatment options within 72 hours of admission.",{"count":54,"type":21},5760,"OBSERVATIONAL","STOP-A is a prospective, multicenter data study aimed at demonstrating the impact of multifaceted support for the implementation of recommendations on the prevention and management of anemia in intensive care, compared to previous practices, on hospital mortality in adult patients hospitalized in intensive care for ≥2 days. The timing of implementation in each center is determined randomly by stepped-wedge randomization.\n\nAs such, this is a pragmatic study that meets the international PRECIS-2 criteria.",[58],"Anemia","2026-08-13",{"date":61,"type":37},"2026-08-18",{"date":63,"type":21},"2026-09-01",{"date":65,"type":21},"2028-03-01",{"name":43,"class":44},27,{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100567968","assessment-of-the-impact-of-intestinal-gas-emission-quality-on-the-postoperative-course-after-abdominal-surgery-100567968","NCT06675097","Assessment of the Impact of Intestinal Gas Emission Quality on the Postoperative Course After Abdominal Surgery","Assessment of the Impact of Intestinal Gas Emission Quality on the Postoperative Course After Abdominal Surgery: Multicentric-center Prospective Study - FLATQUAL- Abdominal Surgery and Gas Transit","FLATQUAL","Inclusion Criteria:\n\n* Patients ≥18 years old\n* Indication for open or laparoscopic abdominal surgery\n* Whose expected length of stay is ≥ 2 days\n\nNon Inclusion Criteria:\n\n* Patients requiring a stomy on the initial surgery\n* Emergency surgery\n* Patient not knowing how to read or write\n* Poor understanding of the French language\n* Person deprived of liberty by judicial or administrative decision\n* Person subject to psychiatric care under duress\n* Person subject to a legal protection measure\n* Person unable to express consent\n* Person objecting to participating in research\n\nExclusion Criteria:\n\n-Immediate post-operative intensive care with patient intubation",{"count":77,"type":21},200,"The recovery of transit after surgery is an important parameter in postoperative evaluation. It generally reflects simple postoperative outcomes and allows the patient to return home.\n\nThe quality of gas recovery after surgery has not been studied to our knowledge, but it is not uncommon for an operated patient to emit some gas considered as a recovery of transit when it is ultimately a false transit preceding a postoperative ileus. Furthermore, intestinal gases and their composition reflect the intestinal microbiota. This microbiota has been shown to be predictive of the appearance of an operative complication. As the analysis of this microbiota cannot be carried out routinely, it is important to be able to use a reflection of this microbiota in routine practice and to correlate it with the surgical outcomes. Intestinal gas therefore seems to be the tool of choice.\n\nThe main objective is to evaluate the association between the appearance of an operative complication and the resumption of gas transit qualified according to its quantity and quality.\n\nThe secondary objectives are to compare the quantity and quality of gases pre- and post-operatively and to define a predictive score for surgical complications, based on the number and quality of post-surgical gases.\n\nData regarding gas transit are collected by the patient in a questionnaire the two days before the surgery and until the patient leaves hospital (or until day 15 post-operative if the patient is still hospitalized).\n\nData regarding possible complications ((defined according to Dindo-Clavien as any deviation from the expected postoperative outcomes within 90 days following surgery) are collected throughout the hospital stay (day 0 : surgery to day 15 post-operatively), during the post-operative consultation (day 30) and during a telephone call to the patient (day 90).\n\nThe expected results are to highlight a correlation between the quality\u002Fquantity of gases and post-operative outcomes. A predictive score for complications could then be proposed and validated during this study.",[80,81],"Postoperative Complication","Recovery, Physiological",[83,84,85,86,87],"transit","surgery","abdomen","stool","gas","RECRUITING","2026-08-06",{"date":91,"type":37},"2026-08-10",{"date":93,"type":37},"2025-01-31",{"date":95,"type":21},"2027-04",{"name":43,"class":44},2,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},"100543882","functional-and-phenotypic-characterization-of-monocytes-in-myeloproliferative-syndromes-100543882","NCT06361641","Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes","Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes-PHEMOP","PHEMOP","Inclusion Criteria:\n\n* Diagnosis of PV, ET, pre-myelofibrosis or primary myelofibrosis according to WHO 2022 criteria (including BOM for ET, premyelofibrosis and primary myelofibrosis)\n* Patient who has not received treatment specific to hemopathy at the time of sampling\n* Obtaining the signature of consent to participate in the study\n* Patient having consented to be included in the \"Malignant Hemopathy\" collection of Angers University Hospital and in FIMBANK database\n\nExclusion Criteria:\n\n* Person not affiliated to a social security scheme or beneficiary of such a scheme\n* Patient with another hemopathy or another active cancer at the time of diagnosis\n* Minor patient at diagnosis (\\\u003C 18 years old)\n* Patient not capable or without agreement from the guardian or legal representative",{"count":107,"type":21},70,[24],"Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms",[111,112,113,114],"Myeloproliferative Neoplasm","Polycythemia Vera","Essential Thrombocythemia","Primary Myelofibrosis",{"date":91,"type":37},{"date":117,"type":37},"2024-05-29",{"date":119,"type":21},"2028-11-19",{"name":43,"class":44},3,{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},"100536281","rat-hemato--return-to-work-after-malignant-hemopathy-100536281","NCT06262789","RAT-HEMATO : Return to Work After Malignant Hemopathy","RAT-HEMATO","Inclusion Criteria :\n\n* Patient with hematological malignancy controlled after treatment\n* Induction\u002Fconsolidation chemotherapy completed (excluding maintenance therapy)\n* Patient aged 18 to 55\n* Patient having worked at least 6 months in the 2 years before diagnosis of hematological malignancy\n* Patient who has not yet returned to work since diagnosis of hematological malignancy\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Patient choosing not to return to work\n* Patient not affiliated to a social security system\n* Patient with legal guardian or legal trustee\n* Patient not understanding French\n* Patient with severe cognitive impairment at diagnosis, incompatible with the study","55 Years",{"count":131,"type":21},264,[24],"Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their \"pre-cancer life\" can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of \"return-to-work self-efficacy\" is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and\u002For beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.",[135,136,137],"Leukemia","Lymphoma","Multiple Myeloma",{"date":91,"type":37},{"date":140,"type":37},"2024-09-27",{"date":142,"type":21},"2027-09",{"name":43,"class":44},9,{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":17,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},"100467584","quality-of-life-and-quality-of-sleep-studies-in-children-with-home-care-ventilation-in-the-west-of-france-100467584","NCT05368662","Quality of Life and Quality of Sleep Studies in Children With Home Care Ventilation in the West of France","Quality of Life and Quality of Sleep Studies in Children With Home Care Ventilation in Two Regions of France Pays de Loire and Bretagne","EQuaViSE","Inclusion Criteria:\n\n* Child aged 6 months to 17 years treated with non-invasive ventilation at home for at least 1 month\n* Follow-up in one of the five centers participating in the study (Angers, Nantes, Le Mans, Rennes and Brest)\n* Informed consent form signed by both parents, or holder of parental authority, for the participation of their child\n* To be affiliated or beneficiary of social security\n\nExclusion Criteria:\n\n* Parents with poor command of the French language, implying not being able to complete the various questionnaires\n* Refusal of the child to participate in the study","6 Months","17 Years",{"count":156,"type":21},160,[24],"Home ventilation in children, invasive or non invasiv,e is an interesting treatment for different disease which cause chronic respiratory impairement. The aim of this treatment is to support alveolar hypoventilation. Concerned diseases are : neuro-muscular disease, upper airways pathologies, whest wall or lung pathologies, central control ventilation disease. Prevalence of home children ventilation is in augmentation in France. The last national study in 2021 about infants show a prevalence of 9.3\u002F100 000. Advantages with home children ventilation in addition of improvement of survey, it can observe improvement of quality of life and improvement of the quality of their sleep. Quality of life is a thematic less studying. Last studies show an impairment of quality of life in all thematics compare to children with no disease but also with infants whith chronic diseases. This study were about few numbers of patients. The aim of this study is to evaluate the quality of life and the quality of sleep in children with home ventilation to complete the actual littérature to improve the respiratory care of this population.",[160,161],"Quality of Life","Non Invasive Ventilation",{"date":163,"type":37},"2026-08-07",{"date":165,"type":37},"2022-11-11",{"date":167,"type":21},"2026-12-14",{"name":43,"class":44},1,{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":180,"studyType":55,"phases":4,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":169},"100384663","impact-of-metabolite-supplementation-to-restore-mitochondrial-dysfunction-during-septic-shock-a-preclinical-study-100384663","NCT04288635","Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study","Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study: MEFDASE Study","MEFDASE","Inclusion Criteria:\n\n* All patients aged 18 or more\n* Patients with criteria for septic shock according to SEPSIS 3 definition (presumed sepsis, with persisting hypotension requiring vasopressors to maintain mean arterial pressure \\> 65 mmHg and having a serum lactate \\> 2 mmol\u002FL despite adequate fluid expansion).\n* Admitted in the ICU of Angers University Hospital\n\nExclusion Criteria:\n\n* Minor patients (aged less 18)\n* Patient subject to legal protection measures\n* Refusal of the patient or his family\n* Preexisting mitochondrial disease\n* Patient with aplasia\n* Pregnant or parturient women",{"count":179,"type":21},55,"28 Days","Septic shock is defined as a subset of sepsis with severe metabolism alterations, leading to organ failure. Septic shock is associated with a high mortality, around 40% according to the SEPSIS 3 definition.\n\nMetabolic alterations are responsible for lactic acidosis, and results in mitochondrial dysfunction.\n\nThis study aims at evaluate the impact of exogenous metabolites on restoring mitochondrial function in septic shock patients with lactate acidosis.\n\nMitochondrial metabolism (quantitative analysis, mitochondrial function) in intact Peripheral Blood Mononuclear Cells (PBMC) will be isolate and analyse from patients at the early phase of septic shock (admission), at day 2 and 4. Participant's medical history will be recorded: renal and liver metabolism, severity scores and outcomes and the need for supportive care in the intensive care unit (ICU) until 28 days after admission.\n\nFurthermore, the investigators will evaluate wether selected metabolites added to the cell culture medium may improve mitochondrial metabolism.",[183,184],"Septic Shock","Multiple Organ Failure",[186],"mitochondrial dysfunction",{"date":91,"type":37},{"date":189,"type":37},"2020-07-09",{"date":191,"type":21},"2027-08-09",{"name":43,"class":44},{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":144},"100607478","inthyx--intubation-strategies-for-patients-with-acute-hypoxemic-respiratory-failure-100607478","NCT07189078","IntHyx : Intubation Strategies for Patients With Acute Hypoxemic Respiratory Failure","IntHyx","Inclusion Criteria:\n\n* Adult patient\n* Patient admitted to intensive care less than 24 hours ago\n* Acute respiratory failure with hypoxemia defined by either:\n\n  * Oxygen therapy ≥ 10 L\u002Fmin via high-concentration mask required for 92 ≤ SpO2 ≤ 98%\n  * High-flow oxygen therapy with FiO2 ≥ 50% required for 92 ≤ SpO2 ≤ 98%\n* Informed consent of the patient or a trusted relative (when the patient is unable to give consent)\n\nExclusion Criteria:\n\n* Acute hypercapnic respiratory failure (defined by PaCO2 \\> 45 mmHg)\n* Cardiogenic pulmonary edema\n* Exacerbation of chronic respiratory disease\n* Respiratory failure requiring long-term oxygen therapy\n* Neuromuscular disease\n* Glasgow Coma Scale score ≤ 12\n* Decision to intubate immediately\n* Invasive mechanical ventilation within the previous 7 days\n* Treatment limitation decisions for intubation\n* Person deprived of liberty by judicial or administrative decision : Person undergoing compulsory psychiatric care, person subject to legal protection measures, Pregnant, breastfeeding, or parturient patient",{"count":77,"type":21},[24],"Acute hypoxemic respiratory failure requires endotracheal intubation and invasive mechanical ventilation in approximately 30-40% of cases, due to severe hypoxemia and\u002For clinical signs of acute respiratory distress. The primary objectives of invasive mechanical ventilation are to reduce respiratory effort and improve oxygenation. However, this intervention is also associated with both direct and indirect adverse effects, mainly linked to the need for sedation and often neuromuscular blockade. These include hemodynamic compromise, neuromuscular weakness, ventilator-induced lung injury, and infectious complications.\n\nAn ideal intubation strategy would therefore strike a balance: avoiding the risks of delayed intubation-such as refractory hypoxemia, excessive respiratory effort, and patient self-inflicted lung injury (P-SILI)-while limiting complications associated with invasive mechanical ventilation by withholding it in patients who might otherwise recover without. To date, the optimal strategy for achieving this risk-benefit balance remains uncertain.\n\nClinical practice suggests a broad consensus on the necessity of intubation when so-called safety criteria are met: severe hypoxemia (SaO₂\u002FFiO₂ ratio \\\u003C 88), marked respiratory distress (use of accessory muscles, thoracoabdominal paradox, respiratory rate \\> 40\u002Fmin), extra-respiratory manifestations of hypoxia (e.g., altered consciousness), and\u002For uncontrolled hemodynamic instability. Beyond these safety thresholds, however, debate persists. Some advocate for earlier intubation-a so-called liberal approach-triggered by predefined hypoxemia criteria (e.g., SpO₂\u002FFiO₂ \\\u003C 110), with the aim of limiting the deleterious consequences of sustained hypoxemia.\n\nIn routine practice, the criteria guiding intubation vary widely between clinicians and cannot be attributed to strong scientific evidence. This study therefore seeks to compare, in a randomized interventional design, the two main strategies currently applied across centers:\n\n* Liberal intubation strategy: prioritizing the prevention of organ dysfunction related to hypoxemia (notably hypoxic cardiac arrest) and the risk of P-SILI.\n* Restrictive intubation strategy: prioritizing the reduction of invasive mechanical ventilation use, with the goal of minimizing ventilation-related harm and its associated therapeutic burden.",[204],"Acute Hypoxemic Respiratory Failure",[206,207],"Randomization","Intubation","2026-08-04",{"date":163,"type":37},{"date":211,"type":37},"2025-12-13",{"date":213,"type":21},"2028-03",{"name":43,"class":44},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":17,"minAge":222,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100649939","changes-in-spatiotemporal-gait-parameters-during-a-digitally-assisted-self-rehabilitation-program-for-elderly-fallers--digiwalk--100649939","NCT07741994","Changes in Spatiotemporal Gait Parameters During a Digitally Assisted Self-rehabilitation Program for Elderly Fallers ( DigiWalk )","DigiWalk","Inclusion Criteria:\n\n* Patients aged 65 and older Fall at least once in the previous 3 months , requiring rehabilitation care from a physical therapist\n* Signed informed consent or consent from a third party (trusted individual, family member, or close relative)\n* Individuals physically capable of following a rehabilitation program (standard care, with or without digital assistance) and of wearing a watch\n* Individuals capable of following a self-rehabilitation program as well as the study procedures independently or with the assistance of a caregiver if needed\n* Patients enrolled in or covered by a social security program\n\nExclusion Criteria:\n\n* A person deprived of liberty by an administrative or judicial decision, a person undergoing involuntary psychiatric treatment, or an adult subject to a legal protective measure\n* Contraindications to rehabilitation programs offered following a fall (standard care, with or without digital assistance)","65 Years",{"count":77,"type":21},[24],"Falls are a health issue that is both common among older adults (affecting 1 in 2 people each year after age 80) and serious due to their traumatic, psychological, and functionally disabling complications. The international literature shows that it is possible to prevent recurrent falls by addressing the risk factors for falls, particularly by combating a sedentary lifestyle and deconditioning through regular standing and mobility exercises as part of a rehabilitation program. As part of France's major national plan to prevent falls among older adults, and at a time when medicine is becoming increasingly personalized, prescribing a digitally assisted self-rehabilitation program for people over 65 following a fall could enable as many people as possible to benefit from rehabilitation that boosts their motivation and reduces the time spent by healthcare professionals, while ensuring high-quality follow-up care.\n\nLNA Santé, in collaboration with the Angers and Nantes University Hospitals, has developed a personalized, digitally assisted fall prevention program (the Stand'hop app) comprising three types of activities: tailored physical exercises, structured lifestyle advice, and an objective measurement of the patient's physical activity. Before moving forward with a larger-scale clinical trial to evaluate the effectiveness of this personalized, digitally assisted fall prevention program, the present study DigiWalk aims to describe changes in walking performance over 7 weeks among older adults who have experienced falls, when the program is used as an adjunct to standard care, compared to changes observed in older adults who have experienced falls and receive only standard care.",[227,228,229],"Aging","Fall","Fall Accident","2026-08-03",{"date":232,"type":37},"2026-08-05",{"date":234,"type":21},"2026-12-05",{"date":236,"type":21},"2028-06-22",{"name":43,"class":44},{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":4},"100643194","a-study-of-the-determinants-of-neurological-outcomes-in-patients-with-acute-respiratory-distress-syndrome-100643194","NCT07629973","A Study of the Determinants of Neurological Outcomes in Patients With Acute Respiratory Distress Syndrome","Etude Des déterminants de l'évolution NEUrologique Des Patients Ayant présenté un Syndrome de Détresse Respiratoire aiguë","NEURDS","Inclusion Criteria:\n\n* Adult patient\n* Patient admitted to the intensive care unit less than 48 hours ago\n* Patient diagnosed with mild, moderate or severe ARDS according to the Berlin classification based on the PaO₂\u002FFiO₂ ratio, with a minimum PEEP set at 5 cmH₂O (16), of pulmonary aetiology:\n\n  * Mild ARDS: 200 \\\u003C PaO₂\u002FFiO₂ \\\u003C 300 mmHg\n  * Moderate ARDS: 100 \\\u003C PaO₂\u002FFiO₂ \\\u003C 200 mmHg\n  * Severe ARDS: PaO₂\u002FFiO₂ \\\u003C 100 mmHg\n* Patients fitted with an oesophageal pressure measurement catheter (Nutrivent, Sidam, San Giacomo Roncole, Italy)\n* Patients registered with or covered by a social security scheme\n* Free and informed consent from the patient or a trusted relative (where the patient is unable to give consent).\n\nExclusion Criteria:\n\n* Patients with a history of central nervous system disorders resulting in cognitive impairment\n* Patients on ECMO\n* Patients admitted for symptomatic central nervous system disorders\n* Patients admitted for acute respiratory distress syndrome following cardiorespiratory arrest.\n* Patients being treated for a psychiatric condition, chronic heavy drinkers, or those undergoing long-term treatment with benzodiazepines, antidepressants or antipsychotics.\n* Pregnant, breastfeeding or labouring patients\n* Individuals subject to a legal protection order\n* Individuals receiving compulsory psychiatric care\n* Individuals deprived of their liberty by judicial or administrative decision",{"count":247,"type":21},150,[24],"Acute respiratory distress syndrome (ARDS) is characterized by pathological pulmonary edema caused by direct or indirect damage to the alveolar-capillary membrane.\n\nIts management relies on etiological treatment, invasive mechanical ventilation, and the use of sedatives and neuromuscular blockers, depending on the patient's condition.\n\nImprovements in patient care have led to an improved prognosis. However, in-hospital mortality remains high (between 35% and 45%). Notably, morbidity among surviving patients is very high and is largely dominated by neuropsychological sequelae. Attention and executive function disorders, confusion, disorientation, or memory impairment are thus found in 70 to 100% of patients following ARDS. These disorders are still present in 46 to 80% of surviving patients one year after ARDS and in 20% of them five years later.\n\nAlthough essential to treatment, mechanical ventilation carries a risk of significant complications. Beyond the risk of infection and complications related to sedation and neuromuscular blockade, the use of mechanical ventilation is associated with a risk of ventilator-induced lung injury (VILI).\n\nThe use of so-called protective ventilation reduces the risk of VILI and improves patient outcomes. However, analysis of relevant physiological parameters shows that the risk of VILI may still exist even when ventilator settings comply with recommendations and the concept of protective ventilation. Driving pressure (which represents Strain) is a good marker of VILI; it represents the distension of the lung with each breath relative to the initial lung volume. Values above 14 cmH₂O are associated with high mortality in patients with ARDS. Inspiratory transpulmonary pressure represents Stress-that is, the pressure that distends the alveoli at the end of inspiration-and is also associated with the risk of VILI. Finally, mechanical power represents the amount of energy delivered to the lung by the ventilator and has been validated as a marker of VILI. The advantage of mechanical power over the other indices described is that it incorporates all components that can lead to VILI.\n\nAmong the various sources of neurological damage during ARDS, inflammatory processes appear to play a major role. Numerous inflammatory mediators (TNF-α, IL-6, IL-8, IL-1β) are secreted during ARDS, and animal studies have demonstrated a link between inflammation and hippocampal damage. Furthermore, cerebral ischemic lesions, exacerbated by systemic inflammation and endothelial activation leading to coagulation activation with thrombus formation, may also contribute to the development of cognitive impairments.\n\nIn addition to the inflammatory processes associated with ARDS, mechanical ventilation itself may have a significant impact on neuroinflammatory damage. Recently, the term \"ventilator-associated brain injury\" (VABI) has been proposed to describe these secondary neurological lesions induced by mechanical ventilation. Studies in mouse and pig models have demonstrated a relationship between the dose and duration of VILI, apoptosis, neuroinflammation, and neuronal damage. An animal study in mice also showed an association between the duration of mechanical ventilation and the onset of cognitive impairments.\n\nDuring brain injury, proteins and neurotransmitters are released and serve as biomarkers of brain damage. Elevated plasma levels of S100B protein indicate astrocyte damage caused by traumatic, anoxic-ischemic, or inflammatory mechanisms. It correlates with neurological prognosis following cardiac arrest, in ischemic or hemorrhagic strokes, in neurodegenerative diseases, and in patients with traumatic brain injury.\n\nClinical studies have shown a negative correlation between elevated S100B protein levels, the MoCA (Montreal Cognitive Assessment) score, and the MMSE (Mini-mental state evaluation ) in patients with OSA (Obstructive Sleep Apnea) or COPD (chronic obstructive pulmonary disease), respectively, indicating an association between this protein and cognitive impairment.\n\nThe investigators therefore hypothesize that mechanical ventilation associated with high mechanical power is linked to a significant risk of brain injury, reflected by elevated serum S100B protein levels and the presence of neurocognitive disorders long after ARDS.",[251,252,253,254,255],"Acute Respiratory Distress Syndrome (ARDS)","s100b","Mechanical Power","Ventilator Induced Lung Injury","Transpulmonary Pressure","2026-07-24",{"date":258,"type":37},"2026-07-27",{"date":260,"type":21},"2026-10-17",{"date":262,"type":21},"2029-10-23",{"name":43,"class":44},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":272,"sex":17,"minAge":18,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":169},"100600604","autosomal-dominant-spinocerebellar-ataxias-and-social-cognition-100600604","NCT07099651","Autosomal Dominant Spinocerebellar Ataxias and Social Cognition","Ataxies SpinoCérébelleuses Autosomiques Dominantes et Cognition Sociale - Etude SoCoSca","SoCoSca","Inclusion Criteria:\n\nFor all participants:\n\n* Men or women aged 18 and over\n* At least 7 years' schooling (CEP level)\n* Ability to read, write and speak French\n* Signed informed consent to participate in the study\n\nFor patients :\n\n\\- With molecularly confirmed autosomal dominant spinocerebellar ataxia (SCA1, 2, 3, 6, 7, 27B)\n\nFor controls:\n\n\\- With no neurological pathology (questioning and neurological examination)\n\nExclusion Criteria:\n\nFor patients and controls:\n\n* Simultaneous participation in another protocol that may interfere with the measurement of the criteria of interest\n* Physical or cultural factors likely to interfere with test performance\n* History likely to interfere with cognition (stroke, cranioencephalic trauma, other neurodegenerative disease, epilepsy, learning disability, alcohol dependence syndrome, psychiatric disorders...)\n* Persons with contraindications to MRI scans\n* Pregnant, nursing or parturient women\n* Persons deprived of their liberty by judicial or administrative decision\n* Persons under compulsory psychiatric care\n* Persons subject to a legal protection measure\n* Persons unable to express their consent\n* Persons not affiliated to or not benefiting from a social security scheme (beneficiary or beneficiary entitled)",true,"100 Years",{"count":156,"type":21},[24],"Spinocerebellar ataxias are a group of rare neurodegenerative diseases, clinically and genetically highly heterogeneous, with an estimated mean prevalence of 2.7 per 100,000 population. The term \"spinocerebellar ataxia\" or \"SCA\" is often used for ataxias of genetic origin of autosomal dominant transmission, which are the subject of this study. Recent studies of social cognition in patients with genetic cerebellar pathologies, and autosomal dominant spinocerebellar ataxia in particular, are still few and far between (around 15 studies), and seem to highlight impairment of basic emotion recognition and theory of mind skills. That said, data have very often been collected on very small samples of patients (sometimes in case study format). They also remain contradictory, including in the examination of the cerebellar anatomoclinical correlates of the deficits. Thus, the question arises as to whether patients with spinocerebellar ataxia also show impairments in emotion recognition and cognitive and affective theory of mind in more ecologically valid dynamic and interactive assessment situations.",[278],"Autosomal Dominant Spinocerebellar Ataxia (SCA1, 2,3,6,7,27B)","2026-07-16",{"date":281,"type":37},"2026-07-20",{"date":283,"type":37},"2025-12-09",{"date":285,"type":21},"2029-01-01",{"name":43,"class":44},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":311},"100241068","phase-2-study-to-improve-os-in-18-to-60-year-old-patients-comparing-daunorubicin-versus-high-dose-idarubicin-induction-regimens-high-dose-versus-intermediate-dose-cytarabine-consolidation-regimens-and-standard-versus-mmf-prophylaxis-of-gvhd-in-allografted-patients-in-first-cr-100241068","NCT02416388","Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","Phase II\u002FIII Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial","BIG-1","Inclusion Criteria (at diagnosis) :\n\n1. Age ≥ 18 years and \\\u003C 61 years\n2. With a newly diagnosed de novo or secondary type AML (post myelodysplastic syndrome MDS or therapy-related AML)\n3. No prior treatment for neither AML (with the exception of hydroxyurea), nor MDS (with the exception of EPO)\n4. ECOG performance status ≤ 3\n5. Absence of severe uncontrolled infection\n6. No cardiac contraindications for the use of anthracyclines : decompensated or uncontrolled heart failure, recent myocardial infarction, current signs of cardiac impairment, uncontrolled arrhythmias, LVEF (left ventricular ejection fraction) \\\u003C 50%\n7. Total bilirubin ≤ 2 x upper limit of normal (UNL), ASAT(SGOT) and ALAT (SGPT) ≤ 2.5 X UNL, creatinine \\\u003C 150 µmol\u002Fl, unless AML-related out of range values\n8. Genetic mutation testing of the FLT3 (FLT3-ITD ou FLT3-TKD) gene, performed in local or central laboratory\n9. Use of appropriate methods of contraception:\n\n   * for patients treated with Midostaurin:\n\n     * women of childbearing potential should use appropriate methods of contaception throughout treatment, and for 5 months post cessation of treatment\n     * men will need to use condoms during intercourse throughout treatment, and for 5 months post cessation of treatment with Midostaurin\n10. Patients who are covered by or beneficiaries of a social security system (Social Security or Universal Medical Coverage)\n11. Patients who have read and understood the information sheet and signed the informed consent form\n\nExclusion criteria (at diagnosis) :\n\n1.Patients with acute promyelocytic leukemia (APL), as confirmed either by t(15;17) or by the presence of PML-RARA fusion transcripts 2.Patients with core binding factor (CBF) AML, as confirmed either by t(8;21), t(16,16) or inv(16), or by fusion transcripts resulting from these cytogenetic abnormalities (RUNX1-RUNX1T1, CBFB-MYH11).\n\n3.Patients with secondary AML arising from myeloproliferative disorders previously known according to the 2008 WHO classification 4.Patients with Ph1+ AML or previous Ph1+ disorder (chronic myelogenous leukemia) 5.Severe psychiatric or organic disorder, supposed to be independent from AML, that would contraindicate treatment, including allogeneic HSCT 6.No psychological, familial, social, or geographic reason that would compromise clinical follow up 7.History of uncontrolled cancer for the last 2 years, with the exception of basal cell carcinoma or carcinoma in situ of the cervix 8.Uncontrolled severe infection 9.Patients with positive serology for HIV-1 and -2, or HTLV -1 and -2, or active hepatitis virus B or C infection 10.Pregnant or lactating women 11.Legal incapacity (patients under tutorship, curatorship or judicial protection)\n\n\\------------------------------------------\n\nFor randomization R4-VOS (post-induction\u002Fsalvage) :\n\nInclusion criteria\n\n1. Patients enrolled in the BIG-1 trial at diagnosis\n2. Patient presenting with AML in first CR or CRp\u002FCRi after induction or one cycle of salvage therapy (confirmed in the 15 days preceding R4-VOS)\n3. Favorable or intermediate risk AML patients, as stratified with BIG-1 prognostic classification\n4. Patients randomized to R2-IDAC arm (intermediate dose cytarabine)\n5. ECOG performance status ≤ 2\n6. Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)\n7. Local clinical laboratory values as follows:\n\n   o Serum creatinine ≤ 2.0 mg\u002FdL\n\n   o Total bilirubin ≤ 1.5 X the upper limit of normal (ULN)\n   * Aspartate aminotransferase (AST) ≤ 2.5 X ULN\n   * Alanine aminotransferase (ALT) ≤ 2.5 X ULN\n8. Signed written informed consent for vosaroxin study (R4-VOS)\n9. Women of childbearing potential must have a negative pregnancy test within 8 days before randomization R4-VOS and commit to the use of effective contraception during the period of treatment and up to 36 days after vosaroxin has been stopped. Men must use effective contraception during the treatment period and up to 96 days after vosaroxin has been stopped.\n\nExclusion criteria\n\n1.Patients classified in the unfavorable risk group according to the BIG-1 protocol classification 2.Complete remission is not attained (CR, CRp\u002FCRi) after induction and\u002For salvage therapy 3.Positive pregnancy test 4.Severe uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever 5.Documented uncontrolled fungal infection (positive blood test and cultures) 6.History of myocardial infarction, unstable angina, cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months before randomization 7.Patient under hemodialysis (HD) or peritoneal dialysis (PD)\n\n\\------------------------------------------\n\nFor randomization R4-DEX (post-induction\u002Fsalvage) :\n\nInclusion criteria\n\n1. Patients enrolled in the BIG-1 trial at diagnosis\n2. Patient presenting with AML in first CR or CRp\u002FCRi after induction or one cycle of salvage therapy (confirmed in the 15 days preceding R4-DEX)\n3. Favorable or intermediate risk AML patients, as stratified with BIG-1 prognostic classification\n4. ECOG performance status ≤ 2\n5. Local clinical laboratory values as follows:\n\n   * Serum creatinine ≤ 150 µmol\u002FL\n   * Total bilirubin ≤ 1.5 X the upper limit of normal (ULN)\n   * Aspartate aminotransferase (AST) ≤ 2.5 X ULN\n   * Alanine aminotransferase (ALT) ≤ 2.5 X ULN\n6. Signed written informed consent for dexamethasone study (R4-DEX)\n\nExclusion criteria\n\n1.Severe uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever 2.Documented uncontrolled fungal infection (positive blood test and cultures 3.History of myocardial infarction, unstable angina, cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months before randomization 4.Patient under hemodialysis (HD) or peritoneal dialysis (PD)\n\n\\--------------------------------------\n\nFor randomization R4-VEN (post-induction\u002Fsalvage) :\n\nInclusion criteria\n\n1. Age 18 - 60 years at inclusion in BIG-1 protocol\n2. diagnosis of AML according to WHO classification de novo or secondary to myelodysplastic syndrome (myelodysplastic syndrome must not have been treated except by ESA, Lenalidomide or non-chemotherapy) or therapy-related AML\n3. Patients included in the BIG-1 protocol\n4. Patients in first CR or CRp\u002FCRi following 1 or 2 courses of induction chemotherapy according to BIG-1 protocol and who are planned to receive consolidation.\n5. Patients stratified within the favorable and intermediate risk groups as defined by BIG-1 protocol\n6. ECOG performance status ≤ 2\n7. Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)\n8. Creatinine clearance ≥ 30 ml\u002Fmin (calculated by the usual method of each institution), total bilirubin ≤ 1.5 times the ULN; ASAT and ALAT ≤ times the upper limit of normal (ULN)\n9. Absence of uncontrolled infection\n10. Women of childbearing potential must agree to use effective contraception without interruption throughout the study and for a further 3 months after the end of treatment\n11. Written signed informed consent\n\nExclusion criteria\n\n1.AML stratified in the unfavorable BIG-1 risk-group. 2.Diagnosis of Acute Promyelocytic Leukemia or CBF AML (ie. AML with t(8;21), t(16,16) or inv(16), or their molecular equivalents RUNX1-RUNX1T1 and CBFB-MYH11) 3.AML secondary to prior myeloproliferative disorder according to WHO classification (2008) and Philadelphia chromosome-positive AML (Ph1+) 4.Absence of CR\u002FCRp\u002FCRi after a maximum of two chemotherapy cycles 5.Severe medical or mental condition precluding the administration of protocol treatments 6.Prior history of cancer unless controlled for at least 2 years and except for basocellular cutaneous cancers and in situ cervix cancers 7.Positive pregnancy test 8.Breast feeding 9.Uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever 10.Documented uncontrolled fungal infection (positive blood test and cultures) 11.Prior venetoclax exposure 12.Known HBV with detectable viral load 13.Known HIV positive patients 14.Known hypersensitivity to any of the study medication 15.History of myocardial infarction, unstable angina, cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months before randomization 16.Patient under hemodialysis (HD) or peritoneal dialysis (PD) 17.Concomitant treatment with cytochrome CYP3A4 inhibitor which cannot be stopped during venetoclax administration ONLY FOR PHASE 1 18.During the phase 2, for patients randomized in the IDAC + Venetoclax arm, if concomitant treatment with cytochrome CYP3A4 inhibitor cannot be stopped, a dose reduction of 70% of venetoclax must be apply\n\n\\--------------------------------------\n\nFor randomization R3 (before AlloHSCT):\n\nInclusion criteria\n\n1. Patients enrolled in the BIG-1 trial at diagnosis\n2. Patient presenting with AML in first CR or CRp\u002FCRi treated in the BIG-1 trial and classified in the intermediate risk group, namely:\n\n   * either initially favorable but poor molecular responders for NPM1 MRD: NPM1 mutation, without FLT3-ITD mutation or with an FLT3-ITD ratio \\\u003C 0.50 and MRD2 positive blood (decrease of less than 4 log from baseline at diagnosis)).\n   * Or initially favorable but requiring two cycles of chemotherapy (a salvage therapy) to obtain the first CR\u002FCRp\u002FCRi\n   * Or other immediate intermediaries\n3. No metastatic or progressive cancer, with the exception of basal cell skin carcinoma and cervical carcinoma in situ\n4. Patients with general condition preserved (ECOG ≤ 3) and with no uncontrolled severe infection\n5. Women of childbearing age must make use of effective contraception\n6. Patients who are covered by or beneficiaries of a social security system (Social Security or Universal Medical Coverage).\n7. Patients who have read and understood the information sheet and signed the informed consent form\n\nExclusion criteria\n\n1. Complete remission is not obtained (CR, CRp\u002FCRi) after induction and\u002For salvage therapy\n2. Patient presenting with AML in first CR or CRp\u002FCRi treated in the BIG-1 trial and classified either in the favorable risk group or the unfavorable risk group\n3. Patients with a severe organ or psychiatric pathology, presumed to be independent of AML and contraindicating the allograft\n4. Patients who, for family, social or geographic reasons, do not wish to be regularly monitored via consultation\n5. Uncontrolled severe infection at the time of inclusion\n6. Serology positive for HIV 1 or 2 or HTLV 1 or 2, or active HBV or HCV viral infection\n7. Pregnant women (beta-HCG positive) or currently breastfeeding\n8. Adult patient who is incapacitated, under wardship, legal guardianship, or under the protection of the courts\n9. Patients under State Medical Assistance (AME)","61 Years",{"count":297,"type":21},3100,[299,300],"PHASE2","PHASE3","This open label, multicenter phase II\u002FIII study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following allogeneic SCT in first CR, after either myeloablative (MAC) or reduced intensity (RIC) conditioning, will also be evaluated. With an adaptative design, this clinical trial could test up to 3 novel AML agents of interest.",[303],"Acute Myeloid Leukemia (AML)",{"date":305,"type":37},"2026-07-17",{"date":307,"type":4},"2015-01",{"date":309,"type":21},"2032-01",{"name":43,"class":44},56,{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":323,"conditions":324,"keywords":328,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":333,"leadSponsor":335,"locationsCount":336},"100631360","pulmonary-embolism-in-patients-with-acute-heart-failure-pehf-study-100631360","NCT07499661","Pulmonary Embolism in Patients With Acute Heart Failure (PEHF Study)","Pulmonary Embolism in Patients With Acute Heart Failure: A Pragmatic Cluster-Randomized Trial (PEHF Study)","PEHF","Inclusion Criteria:\n\n* Adult patient (≥18 years)\n* Admission to the emergency department or cardiology unit of a participating center\n* Recent onset or worsening dyspnea and\u002For orthopnea\n* Diagnosis of acute heart failure defined by recent dyspnea associated with at least one of the following:\n\n  * Bilateral pulmonary crackles on auscultation and\u002For peripheral edema\n  * Signs of pulmonary congestion on chest X-ray or lung\u002Fcardiac ultrasound\n  * Elevated natriuretic peptide levels (BNP or NT-proBNP)\n  * Documented history of heart failure (known chronic heart failure or prior hospitalization for acute heart failure)\n* Patient affiliated with or beneficiary of a social security system\n* Patient able and willing to provide free, informed, and written consent\n\nExclusion Criteria:\n\n* Shock state suggesting cardiogenic shock and\u002For severe pulmonary embolism\n* Severe respiratory distress at inclusion preventing appropriate positioning or performance of imaging examinations\n* Evidence of acute coronary syndrome on electrocardiogram at admission\n* Severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin)\n* Known hypersensitivity or allergy to iodinated contrast agents\n* Ongoing therapeutic anticoagulation for more than 48 hours prior to admission\n* Hospitalization for more than 48 hours prior to inclusion\n* Inability to ensure 90-day follow-up (e.g., end-of-life situation, no fixed address, patient not reachable)\n* Inadequate understanding of the French language preventing proper study information and consent\n* Pregnant, breastfeeding, or postpartum women\n* Individuals under legal protection or other vulnerable populations, including minors and protected adults, in accordance with applicable public health regulations (Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the French Public Health Code)",{"count":321,"type":21},740,[24],"This study focuses on two serious and common medical conditions: heart failure and pulmonary embolism (a blood clot in the lungs). Heart failure happens when the heart cannot pump blood effectively, and it is one of the main reasons older adults are admitted to the hospital. Pulmonary embolism can be life-threatening and may worsen heart failure or even trigger it.\n\nDoctors believe that pulmonary embolism may often go undetected in patients who come to the hospital with symptoms of acute heart failure, such as sudden shortness of breath. This is because both conditions can cause similar symptoms, making it difficult to tell them apart. As a result, doctors may sometimes assume the symptoms are only due to heart failure and not investigate further for a possible blood clot.\n\nHowever, missing a pulmonary embolism can have serious consequences. Studies suggest that some patients with heart failure who die may actually have had an undiagnosed pulmonary embolism. Current medical guidelines recommend checking for pulmonary embolism when the cause of breathing problems is unclear, but in real-life practice, this is not always done.\n\nThe goal of this study is to find out whether pulmonary embolism is underdiagnosed in patients with suspected acute heart failure and whether systematically testing for it could improve patient outcomes.\n\nTo do this, the study will compare two approaches in several hospitals. In half of the hospitals, doctors will follow their usual practice and decide case by case whether to test for pulmonary embolism. In the other half, doctors will systematically test all eligible patients for pulmonary embolism using recommended diagnostic methods.\n\nAdult patients admitted with recent or worsening breathing difficulties and signs of acute heart failure may be included in the study, provided they give their consent. Researchers will collect information about their symptoms, tests, diagnosis, and treatments.\n\nPatients will be monitored during their hospital stay and for three months afterward. The study will track important outcomes such as survival, new blood clots, bleeding events, repeated hospital visits for breathing problems, and overall time spent in the hospital.\n\nThe researchers expect to include about 740 patients in total. They estimate that pulmonary embolism may be found in about 1% of patients with usual care, but up to 5% when doctors systematically look for it.\n\nThis study aims to better understand how often pulmonary embolism occurs in patients with acute heart failure and whether more systematic testing could lead to earlier diagnosis and better care. The results could help improve medical practice and reduce complications or deaths related to missed diagnoses.",[325,326,327],"Acute Heart Failure (AHF)","Pulmonary Embolism (Diagnosis)","Venous Thromboembolism",[329],"Cluster-randomized trial","2026-07-15",{"date":305,"type":37},{"date":330,"type":37},{"date":334,"type":21},"2028-10",{"name":43,"class":44},10,{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":22,"phases":347,"briefSummary":348,"conditions":349,"keywords":352,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":369},"100592225","outpatient-versus-inpatient-care-pathway-for-intra-arterial-treatment-of-primary-liver-cancer-choc-100592225","NCT06990659","Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)","CHOC - Implementation and Evaluation of an Ambulatory Care Pathway for Intra-arterial Treatment of Primary Liver Cancer: Study Protocol for a Multicentre Randomised Controlled Hybrid Type 1 Trial Implémentation et évaluation d'un Parcours de Soin Ambulatoire Pour Les Patients traités Par Voie Intra-artérielle d'un Cancer Primitif du Foie : Essai Multicentrique contrôlé randomisé","CHOC","Inclusion Criteria:\n\n* Age ≥ 18 years\n* HCC or iCCA diagnosed according to the criteria of the European Association for the Study of the Liver (2024) or histologically proven.\n* Patient with HCC or iCCA eligible for intra-arterial treatment (transarterial chemoembolization \\[TACE\\] or transarterial radioembolization \\[TARE\\]), with no prior intra-arterial treatment of the same type as the one planned in the trial:\n\n  * no prior TACE for patients included for TACE;\n  * no prior TARE for patients included for TARE. Prior intra-arterial treatment of the other type is allowed (prior TACE before TARE, or prior TARE before TACE). Prior non-intra-arterial treatments are allowed.\n* If TACE is proposed at the multidisciplinary tumour board (RCP):\n\n  * Patient Child-Pugh \\\u003C B8\n  * Single or multiple HCC\n  * Absence of lobar or truncal portal obstruction\n  * Absence of bile duct dilatation\n* If treatment by TARE proposed in RCP:\n\n  * Absence of truncal portal tumor invasion\n  * Uni-lobar tumor invasion (except for centrohepatic iCCA)\n  * Total bilirubin \\\u003C 20 mg\u002Fl (or 35 µmol\u002FL)\n* Patient affiliated to or benefiting from a social security scheme\n* Patient having signed an informed consent form\n\nExclusion Criteria:\n\n* Technical contraindication or morphological elements of predictable technical difficulty\n* Planned combined same-day therapeutic strategies at the index procedure (e.g., TACE combined with percutaneous ablation) are not allowed; sequential (non-same-day) treatments are allowed.\n* Chronic renal insufficiency (Clairance \\\u003C 30 ml\u002Fmin)\n* Known allergy to a contrast agent or chemotherapy agent\n* inability to participate in ambulatory care (inability to understand and follow discharge instructions, lack of reliable telephone access, absence of a responsible accompanying adult for the first night after discharge, or inability to access urgent care in a timely manner if symptoms occur)\n* Patient previously included in the study\n* Patient who, for psychological, social, family or geographical reasons, could not be regularly monitored, patient who, for psychological, social, family or geographical reasons, could not be followed regularly\n* Concomitant disease or severe uncontrolled clinical situation\n* Severe uncontrolled infection\n* Pregnant, breast-feeding or parturient woman\n* Person deprived of liberty by judicial or administrative decision\n* Person under compulsory psychiatric care\n* Person under a legal protection measure\n* Person unable to give consent",{"count":346,"type":21},206,[24],"Randomized multicentre trial comparing two care organisations (ambulatory vs conventional inpatient) for patients undergoing transarterial chemoembolization (TACE) or radioembolization (TARE) for primary liver cancer (Hepato Cellular Carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA)). Patients are followed for 7 months to assess patient satisfaction, safety and clinical outcomes. A qualitative implementation study and a medico-economic evaluation (cost analysis and 5-years budget impact analysis) are embedded to assess acceptability, adoption, feasability, and sustainability and to inform scaling.",[350,351],"Hepato Cellular Carcinoma (HCC)","Intrahepatic Cholangiocarcinoma",[353,354,355,356,357,358,359,360,361,362],"ambulatory care","hospitalization","Hepato cellular carcinoma","Patient satisfaction","randomized trial","chemoembolization","radioembolization","Intrahepatic","Cholangiocarcinoma","Primary liver cancer",{"date":305,"type":37},{"date":365,"type":37},"2025-12-18",{"date":367,"type":21},"2028-12-17",{"name":43,"class":44},19,{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":393},"100506947","nac--nafld-and-cushing-100506947","NCT05881005","NAC- NAFLD And Cushing","Prévalence de la stéato-fibrose hépatique Dans le Syndrome de Cushing","NAC","Inclusion Criteria:\n\n* Age \\> 18 years\n* Active Cushing's syndrome\n\nExclusion Criteria:\n\n* Other common causes of chronic liver disease (HBV, HCV, haemochromatosis, alcohol)\n* Contraindication to MRI",{"count":379,"type":21},100,[24],"Cushing's Syndrome is a rare disease resulting from prolonged exposure to high levels of circulating cortisol. Clinical manifestations are variable but many patients present a metabolic syndrome (abdominal obesity, insulin resistance, dyslipidemia, hypertension). With regard to the liver, experimental data have shown that excess cortisol leads in an increase in lipogenesis and a reduction in the oxidation of fatty acids. This, in association with an accumulation of visceral adipose tissue and deregulation of adipokines, may contribute to the development of hepatic steatosis in animals. However, few data is available in humans with only one study of 50 patients with Cushing's syndrome estimating the prevalence of hepatic steatosis at 20%.\n\nNAFLD (Non-Alcoholic Fatty Liver Disease), is defined as the presence of hepatic steatosis in the absence of secondary causes of intrahepatic fat accumulation. It is a heterogeneous disease ranging from simple liver steatosis, whose prognosis is generally considered to be benign, to inflammation (NASH, Non-Alcoholic Steato-Hepatitis) which may progress to fibrosis, cirrhosis and an increased risk of hepatocellular carcinoma. The prognosis for NAFLD is mainly related to the severity of hepatic fibrosis.\n\nIn Cushing's syndrome, normalization of cortisol production is the most effective strategy to improve co-morbidities associated with hypercortisolism. However, some of these complications, especially the metabolic co morbidities, could not be completely reversible and no data is available about resolution of hepatic steatosis.",[383,384],"Cushing Syndrome","Fatty Liver Disease","2026-07-08",{"date":387,"type":37},"2026-07-10",{"date":389,"type":37},"2023-09-28",{"date":391,"type":21},"2029-09-28",{"name":43,"class":44},7,{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":405,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":169},"100641478","post-operative-pain-and-vagal-stimulation-100641478","NCT07659314","Post Operative Pain and Vagal Stimulation","\"Evolution of Postoperative Anal Pain Following Elective Proctological or Rectal Surgery Under the Effect of Transcutaneous Vagal Auricular Stimulation: a Feasibility Study - VAGANAL - Postoperative Pain and Vagal Stimulation\"","VAGANAL","Inclusion Criteria:\n\n* Adult patient\n* Underwent anal or rectal surgery via the transanal route\n* Managed on an outpatient basis or in conventional hospitalization\n* Having signed a consent to participate in the study\n\nExclusion Criteria:\n\n* Patient operated on as an emergency\n* Rectal surgery via abdominal approach or requiring an abdominal approach during the procedure\n* Known epileptic patient\n* Patient with a pacemaker\n* Patient refusing to participate in the study\n* Pregnant, breastfeeding, or laboring woman\n* Patient not affiliated with a social security scheme\n* Person deprived of liberty by judicial or administrative decision\n* Person subject to compulsory psychiatric care - Any contraindication mentioned in the instructions for use of the medical device under investigation\n\nExclusion Criteria:\n\n* Unscheduled conversion from the transanal route to the abdominal route during surgery","120 Years",{"count":404,"type":21},50,[24],"Anorectal surgery is a type of surgery that can cause anal pain, particularly in the context of hemorrhoid surgery or anal fissure surgery. Generally, the period of discomfort related to the pain lasts about two weeks. There is a nerve (the vagus nerve) whose stimulation via a probe placed in the ear can reduce stress and chronic pain. Its ease of use makes it a promising tool for treating pain. Vagal auricular stimulation could be an interesting option in the management of postoperative pain of the anus and rectum. Its efficacy or feasibility in this context has never been evaluated.\n\nThe aim of this study is to evaluate the feasibility in this context and to assess the extend of pain reduction associated with perioperative nerve vagus stimulation by a medical device (Transcutaneous Electrical Nerve Stimulator (TENS ECO Plus)). It is offered to adult patients undergoing transanal anal or rectal surgery on an outpatient or inpatient basis as part of a scheduled procedure.\n\nPatients to be included in the study are selected during the initial pre-operative consultation with the surgeon. Once the surgical indication is confirmed and the patient fulfills the study eligibility criteria, the investigator provides them with oral information about the study. The patient is also given an information sheet (written in language understandable to the patient) and a consent form.\n\nDuring this initial visit, demographic data and information regarding the surgical indication are collected.\n\nStimulation begins two days before surgery (twice daily), followed by stimulation on the morning of surgery, one hour before arrival in the operating room. Successful completion of the stimulation, as well as any complications, are recorded in the patient diary.\n\nOn the day of surgery (day 0), data concerning the procedure and the maximum visual analogue scale (VAS) are collected in the recovery room. Analgesic consumption is also recorded.\n\nOn the evening of the procedure, stimulation is performed and adherence is recorded.\n\nMaximum and mean VAS are collected on postoperative day 1 and then daily in the patient diary for 15 days.\n\nVagus nerve stimulation is performed morning and evening for 15 days. VAS scores, adherence, analgesic consumption, the date of the first bowel movement and its painfulness, as well as any complications related to the stimulation are noted in the patient diary. On day 3 (+\u002F- 2 days) after the procedure, and at the end of the 15-day postoperative period, the patient will be contacted by phone or text message by the investigator team to remind them to complete the notebook.\n\nOn day 30 (+\u002F- 5 days), the patient returns for a follow-up visit. The patient diary and equipment are collected. Complications are recorded, as well as quality of life during the postoperative month (SF-36 form).\n\nFor patients, the expected benefits are significant, as postoperative quality of life is expected to improve through reduced pain. Furthermore, decreasing the use of step II and III analgesics should shorten the recovery period and promote better overall recovery.",[408,409,410],"Rectal Surgery","Pain (Visceral, Somatic, or Neuropathic)","Vagal Nerve Stimulation","2026-06-29",{"date":413,"type":37},"2026-07-01",{"date":415,"type":21},"2026-11-09",{"date":417,"type":21},"2028-01-09",{"name":43,"class":44},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":426,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":430,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":444},"100492966","screening-in-primary-care-of-advanced-liver-fibrosis-in-nafld-andor-alcoholic-patients-100492966","NCT05699018","Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and\u002For Alcoholic Patients","SOPRANO","Inclusion Criteria:\n\n* NAFLD and\u002For ALD patient defined by at least 1 of the following criteria:\n\n  * Excessive alcohol consumption: higher than 210 g \u002F week (men), or 140 g \u002F week (women)\n  * Type 2 diabetes\n  * at least 2 metabolic factors among BMI higher than or equal to 25 kg \u002F m 2; Elevated blood pressure (antihypertensive drug, or systolic blood pressure higher than or equal to 130mmHg, or diastolic blood pressure higher than or equal to 85mmHg), Dyslipidemia (lipid-lowering drug, or HDL cholesterol lower to 40mg\u002Fdl (men) \u002F 50mg\u002Fdl (women), or triglycerides higher than or equal to150mg\u002Fdl); Hyperferritinemia (higher than upper limit of normal from the laboratory)\n  * Bright liver at ultrasonography without steatosis-inducing drug(systemic corticosteroids, tamoxifen, amiodarone, methotrexate)\n\nFollowing a protocol amendment, the 3 last investigating primary care centres will include NAFLD and\u002For ALD patients according to these updated criteria:\n\n* Excessive alcohol consumption: \\>210 g\u002Fweek in men or \\>140 g\u002Fweek in women,\n* AND\u002FOR type 2 diabetes treated with insulin and\u002For at least two other anti-diabetic treatments,\n* AND with the following stratification:\n\n  30% with excessive alcohol consumption 65% with type 2 diabetes treated with insulin and\u002For at least two other anti-diabetic treatments 5% with both conditions (excessive alcohol consumption, AND type 2 diabetes treated with insulin and\u002For at least two other anti-diabetic treatments)\n* Patient's agreement to have a blood sample collected in a local laboratory participating in the study\n* Subjects covered by or having the rights to medical care assurance\n* Written informed consent obtained from subject\n\nExclusion Criteria:\n\n* Already ongoing specialized follow-up for a chronic liver disease\n* Altered health status with poor short-term prognosis, not compatible with a screening procedure\n* Decompensated cirrhosis (hepatic encephalopathy, jaundice, ascites, variceal bleeding, hepatorenal syndrome)\n* Acute infection\n* Pregnancy, breastfeeding\n* Persons in detention by judicial or administrative decision\n* Person admitted to a health or social establishment for purposes other than research\n* Person subject to a legal protection measure\n* Person unable to express consent","40 Years","80 Years",{"count":429,"type":21},1788,[24],"The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and\u002For ALD from primary care centers.",[433,434,435],"Non-alcoholic Fatty Liver Disease (NAFLD)","Alcoholic Liver Disease (ALD)","Liver Fibrosis","2026-06-26",{"date":438,"type":37},"2026-06-30",{"date":440,"type":37},"2023-03-13",{"date":442,"type":21},"2026-09-12",{"name":43,"class":44},13,{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":17,"minAge":453,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":455,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":472},"100523656","evaluation-of-a-prototype-for-an-innovative-room-for-the-elderly-100523656","NCT06098534","Evaluation of a Prototype for an Innovative Room for the Elderly","Evaluation d'un Prototype de Chambre Innovante adaptée au Grand Age","HOSPISENIOR","Inclusion Criteria:\n\n* Age ≥ 75 years\n* Admission in a short-stay geriatric department following initial emergency care department or direct entry from home\n* Hospitalization in single room: Hospi'Senior or conventional\n* Affiliation to a social security scheme\n* Informed consent to participate in the study from the patient or his\u002Fher representative (tutor\u002Fcurator if applicable, or in order of priority a trusted person, the family or a person with whom the person concerned has a close and stable relationship)\n\nExclusion Criteria:\n\n* Contraindication to study participation at the discretion of the medical team\n* Hospitalization for more than 3 days (\\>3 days) in the short-stay geriatric unit\n* Hospitalization in a double room\n* Planned hospitalization\n* Poor understanding of the French language\n* Patient under safeguard of justice","75 Years",{"count":77,"type":21},[24],"The Groupement de Coopération Sanitaire des Hôpitaux Universitaires du Grand Ouest (GCS HUGO) (health cooperation group for university hospitals in the west of France), is proposing to improve the quality of geriatric care by modernizing hospital rooms. The GCS HUGO has embarked on a project to co-design a hospital room adapted for the elderly, called \"Hospi'Senior\", with the help of the \"Dépendance et Grand âge\" (Dependency and Old Age) steering committee, made up of experts from HUGO's establishments and experts from several companies.",[458],"Elderly Inpatients",[460,461,462,463,464],"Prototype","Care","Hospital Room","Elderly","Innovation","2026-06-25",{"date":411,"type":37},{"date":468,"type":37},"2023-11-09",{"date":470,"type":21},"2028-02-10",{"name":43,"class":44},5,{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":272,"sex":481,"minAge":18,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":22,"phases":484,"briefSummary":485,"conditions":486,"keywords":489,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":169},"100495215","impact-of-time-on-sexual-function-fsfi-score-after-hysterectomy-100495215","NCT05728281","Impact of Time on Sexual Function (FSFI® Score) After Hysterectomy","Recommended Time to Resume Sexual Activity After Hysterectomy: Impact on Sexual Function (FSFI® Score) and Complication Rate ISHYS Study","ISHYS","Inclusion Criteria:\n\n* Patient ≥ 18 years old,\n* Francophone,\n* Sexually active,\n* Receiving a conservative or non-conservative total hysterectomy for benign pathology\\*,\n* Having signed a consent form. All surgical approaches are considered, laparoscopic approach with laparoscopic or vaginal closure, vaginal approach and laparotomy.\n\n  \\*The indications for the procedure selected for this study include:\n* Menometrorrhagia,\n* Fibroids,\n* Adenomyosis,\n* Endometriosis,\n* Pelvic statics disorder,\n* Cervical dysplasia,\n* Endometrial cancer not requiring lymph node dissection or additional treatment.","FEMALE",{"count":483,"type":21},142,[24],"In France, more than 62 000 hysterectomies are performed each year. Female sexual function is the result of multiple psychological, social and physiological factors. There is no information in the current literature about the optimum time between the surgery and the sexual relation resumption. The primary outcome is to assess the impact of advising time between hysterectomy and sexual relation resumption by using FSFI® score. Secondaries outcomes are: to describe and compare post-operative complications in the two groups of the study, to describe the follow-up of the recommendation concerning time between surgery and sexual relation resumption and to describe why this recommendation was not followed. This study is based on 4 questionnaires: FSFI® pre-operative and post-operative, pre-operative questionnaire and post-operative questionnaire. This is a monocentric, comparative, of superiority, randomised and prospective study. Patients are randomised into two groups: sexual relation resumption advised 4 weeks after surgery, or 8 weeks. The inclusion criteria are more than 18 years, francophone, in sexual activity, scheduled for a total hysterectomy for benign indication (menometrorrhagia, fibroma, adenomyosis, endometriosis, pelvic floor disorders, low-grade endometrial cancer), considering vaginal, laparoscopic and abdominal approach, and a written consent. Non-inclusion criteria are illiteracy, cognitive disorders, without social security, deprived liberty by judicial or administrative decision, psychiatric care, patient with legal protection, patient incapable of giving consent. If our conclusions confirmed our hypothesis, it can improve clinical practices by providing additional informations for surgeon and patient, to undergo this surgery as serenely as possible.",[487,488],"Time Between Hysterectomy and Resumption of Sexual Relations","Sexual Function",[490,491,492,493],"benign gynaecological disease","hysterectomy","sexual function","FSFI® score",{"date":436,"type":37},{"date":496,"type":37},"2023-06-05",{"date":498,"type":21},"2027-10-05",{"name":43,"class":44},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":22,"phases":509,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":169},"100477601","functional-study-to-indentify-genetic-etiology-of-rare-diseases---origin-100477601","NCT05499091","Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN","ORIGIN","Inclusion Criteria:\n\nPatient :\n\n* Child or adult affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood.\n* Patient included inside the BaMaRa (French rare disease national data bank) database dedicated to the rare diseases.\n* Patient Affiliated to the French social security system.\n* Patient consent form or legal representative consent form obtained.\n\nPatient's parent :\n\n* Parent of a patient affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood.\n* Parent included in the BaMaRa database.\n* Parent affiliated to the French social security system.\n* Parent consent form obtained for himself\u002Fherself.\n\nPatient's brother or sister :\n\n* Brother or sister of a patient (underage or adult) affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood.\n* Brother or sister included in the BaMaRa database.\n* Brother or sister affiliated to the French social security system.\n* Brother or sister consent form obtained for themselves or from their legal representative.\n\nExclusion Criteria:\n\n* Poor understanding of the French language\n* Legal of administrative liberty deprivation\n* Psychiatric force care",{"count":508,"type":21},1200,[24],"Next generation sequencing (NGS) allows some better diagnostic results, particularly, in the rare diseases field. At a twenty five percent rate, those exams highlight some variants which are not yet described in human pathology. The relationship between a variant found inside a candidate gene and a pathology, is able to be confirmed by functional studies at a protein level. This study aims to build a biological collection to feed further functional studies to confirm the relationship between NGS identified variants, and the clinical signs and symptoms.",[512,513],"Rare Diseases","Genetic Disease",{"date":411,"type":37},{"date":516,"type":37},"2022-10-10",{"date":518,"type":21},"2045-10-10",{"name":43,"class":44},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":22,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":541},"100429093","a-study-comparing-the-effectiveness-of-endorotor-versus-radiofrequency-in-treating-barretts-esophagus-100429093","NCT04867590","A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus","A Controlled, Randomised Multicenter Study Comparing the Effectiveness of EndoRotor (New Treatment Technique) Versus Radiofrequency (Reference Technique) in Treating Barrett's Esophagus Complicated by Dysplasia","ENDOBARRETT","Inclusion Criteria:\n\n* Adult patients presenting Barrett's esophagus of a size between 2 cm and 6 cm in the height of the longest tonguea with low to high grade dysplasia that is histologically proven or with a superficial non-invasive adenocarcinoma that has been resected a The total height of the BE is evaluated according to the Prague classification, with the height of the circumferential segment between 0 cm (non-circumferential segment) and 6 cm (segment shaped like a full sleeve for 6 cm), referred to as C0 to C6, and the height of the longest tongue between 2 cm and 6 cm (M2- M6).\n* Patients must have signed the consent form in order to participate in the study\n* Patients are pre-included (signature of consent) before the histological confirmation of dysplasiab and\u002For superficial non-invasive adenocarcinoma that allows the patient to be included in the study.\n\nExclusion Criteria:\n\n* Individuals over 85 years old\n* Women who are pregnant, breastfeeding or in labour\n* Individuals in detention through judicial or administrative decision\n* Individuals who are the subject of psychiatric treatment under duress\n* Individuals who are subjects of legal protection measures\n* Individuals who are in no state to give their consent\n* Individuals who do not understand French or do not know how to read\n* Individuals who are not part of a social security program or benefit from such a scheme\n* Those with active peptic and\u002For radiation-induced or complicated esophagitis at the time of treatment\n* Presence of a visible lesion that is suspected to be esophageal cancer confirmed by biopsies\n* Anterior resection of invasive adenocarcinoma using endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) with invasion of the lateral and\u002For deep margin, adenocarcinoma of poorly differentiated characteristics or sub-mucosal invasion \\> 500µm (pT1b)\n* All preliminary ablation treatments or dilation for esophageal stenosis\n* Significant esophageal stenosis: cannot be passed with a standard gastroscope\n* Presence of esophageal varices or portal hypertension\n* Anticoagulant treatment that cannot be stopped before the intervention (excluding 100 mg maximum per day of aspirin in single-drug treatment) or any haemostasis problems that cannot be corrected\n* Having a contraindication regarding anaesthesia\n* Patients incapable of taking proton pump inhibitors (PPIs) orally.",{"count":529,"type":21},140,[24],"Barrett Esophagus is a common pathology, with an estimated prevalence of 1.6% at risk of progression to precancerous mucosa (low to high grade dysplasia). The incidence of adenocarcinoma on BE is 0.5% per year. In the event of dysplasia or cancer in situ, it is currently recommended at international and particularly European level to eradicate BE. The treatment techniques used to date carry out thermal destruction of the BE, in particular by radiofrequency. Eradication of dysplasia is achieved in 81% to 100% and disappearance of BE in 73% to 87% of cases. It requires an average of 3 destruction sessions. RF does not allow histological analysis after destruction of BE, but the risk of progression to neoplasia is estimated at 7.8\u002F1000 persons per year. This risk could be due to the presence of glands buried in the esophageal mucosa. Indeed, these glands are not destroyed by thermal ablation methods, and remain invisible during endoscopic controls.\n\nA new treatment technique using the Endorotor® system allows mechanical resection of the entire mucosa in one session of treatment. In addition, the cost of these thermal destruction techniques currently limits their wider diffusion. It is therefore legitimate to propose a less expensive and probably more effective alternative technique.",[533,534],"Barrett Esophagus","Dysplasia",{"date":438,"type":37},{"date":537,"type":37},"2022-03-25",{"date":539,"type":21},"2031-07-25",{"name":43,"class":44},17,{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":22,"phases":550,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":169},"100597790","evaluation-of-the-value-of-ultrasound-measurement-of-stomach-diameter-in-predicting-postoperative-nauseavomiting-100597790","NCT07063069","Evaluation of the Value of Ultrasound Measurement of Stomach Diameter in Predicting Postoperative Nausea\u002FVomiting","EVOL2","Inclusion Criteria:\n\n* Major patient\n* Indication for major abdominal surgery (submesocolic, parietal, left pancreas or liver)\n* Patient affiliated to or benefiting from a social security scheme\n\nNon-inclusion criteria\n\n* Patient refusal to participate in study\n* Need for immediate post-operative ICU stay\n* Surgery performed as an emergency\n* Esophageal, gastric or cephalic pancreatic surgery\n* Person deprived of liberty by judicial or administrative decision\n* Person under compulsory psychiatric care\n\nExclusion Criteria:\n\n* Discharge with nasogastric tube\n* Immediate admission to post-operative intensive care unit",{"count":247,"type":21},[24],"The advent of enhanced rehabilitation after surgery has helped to reduce surgical stress, thereby improving postoperative outcomes by reducing the time it takes for patients to recover their transit and autonomy.\n\nDespite this, some 10-30% of patients undergoing abdominal surgery will experience postoperative ileus or nausea\u002Fvomiting. In addition to increasing the length of hospital stay, these complications increase patient discomfort and, above all, the risk of inhalation pneumonitis.\n\nWith the advent of enhanced rehabilitation, patients are receiving less drainage, particularly nasogastric drainage, which is now virtually outlawed in scheduled sub-mesocolic abdominal surgery.\n\nIn a recent international multicenter study of patients undergoing colorectal surgery, the authors reported that less than 10% of patients received a nasogastric tube routinely, and that 20% received it for clinical reasons (before or after nausea\u002Fvomiting). The authors also reported an overall inhalation pneumonitis rate of 4.2%. The authors concluded from this study that nasogastric tubes should not be inserted routinely, but that delay in nasogastric tube insertion was a risk factor for pneumopathy.\n\nAs the onset of postoperative pneumopathy is associated with a risk of mortality, it seems important to predict its risk of onset in order to target patients who could benefit from early nasogastric tube placement.\n\nA recent study carried out in the visceral surgery department of the CHU d'Angers evaluated the evolution of gastric distension. One of the objectives of the ancillary study was to evaluate the interest of the ratio of gastric antrum distension measurement in 2 axes (longitudinal and axial) at D2 postoperative \u002F D preoperative.\n\nAs this was an ancillary study of a preliminary study, the number of events was 12, making it impossible to assert with high power that the appearance of nausea\u002Fvomiting is linked to the ratio described above. An observational study including more patients is therefore needed to confirm this hypothesis before carrying out a randomized controlled trial.",[553],"Patient With Indication for Major Abdominal Submesocolic, Parietal, Left Pancreatic or Liver Surger","2026-06-24",{"date":411,"type":37},{"date":557,"type":37},"2025-08-08",{"date":559,"type":21},"2028-03-19",{"name":43,"class":44},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":22,"phases":570,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":574,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":393},"100574699","transcriptomic-approach-for-the-identification-and-prioritization-of-genome-variants-in-neurodevelopmental-disorders-with-malformation-100574699","NCT06762678","Transcriptomic Approach for the Identification and Prioritization of Genome Variants in Neurodevelopmental Disorders With Malformation","ATOMICS","Inclusion Criteria :\n\n* children or adult without any age limit, with neurodevelopmental disorders defined by :\n* between 0 and 5 years old with severe developmental delays regarding motor and\u002For language acquisitions, and\u002For social communication disorders,\n* \\> 6 years old with intellectual deficiency whatever the severity (with if available, neuropsychological evaluation), with potential associated manifestations such as epilepsy and\u002For autism, and\u002For behaviour troubles and\u002For attention deficit hyperactivity disorder ;\n* with developmental anomalies and\u002For dimorphism ;\n* without any evidence of clinical diagnosis\n* negative chromosomal microarray and\u002For exome sequencing\n* negative fragile X syndrome\n* skin biopsy feasible or RNA sample extracted from fibroblast culture, available to be used in a research context inside the lab center\n* consent obtained from the participant or, consent from legal representatives for a minor patient or a patient unable to consent\n* participant affiliated to the french security regimen or equivalent\n\nExclusion Criteria:\n\n* Neurodevelopmental disorders with developmental anomaly from non genetic causes or highly evident diagnosis for which a molecular test is available in routine practices and whose the cost is inferior than the cost of the genome and the RNA sequencing\n* unwillingness to participate, from the patient or from the legal representatives\n* Pregnant or lactating women",{"count":569,"type":21},58,[24],"Three million persons in France are impacted by rare diseases. Amid the 7000 different diseases which are identified today, neurodevelopmental disorders are the main symptoms found interesting 35 000 birth every years, according to the French Health Authority. In half of these cases, patients are under 5 years old and a molecular diagnosis is only available in 50% of them, associated with a diagnostic wandering exceeding 5 years for 25% of every patients.\n\nHigh throughput DNA sequencing technologies are powerful tools to elucidate new causative variants. Although the diagnostic yield was refined by DNA-seq, data interpretation and technology limits remain the two major obstacles which still need be overcame. Missing a molecular diagnosis through a genomic approach alone highlight the need to integrate multi-omic approaches such as Ribonucleic Acid sequencing. This sequencing level allows new insight such like the evidence of aberrant gene expression, mono allelic allele expression, or abnormal alternative splicing. It makes possible too, to detect variants which are unable to be found via genome sequencing only.\n\nRecently, a diagnostic performance improvement has been described trough the association of the two technics, i.e. Ribonucleic Acid-seq and genome sequencing, in a context of neuromuscular diseases. However, only few studies were carry out on neurodevelopmental disorders in addition with malformative features. Angers's team demonstrated by the end of 2022, a diagnostic results enhancement by carrying genome sequencing plus Ribonucleic Acid-seq at the same time on patient with previously exome negative analysis. Moreover in 2023, Dekker et al. work shed light on a diagnostic yield improvement via the same analytic schema.\n\nIn face of those first observations, the ATOMICS study aims to evaluate the diagnostic contribution of Ribonucleic Acid-seq paired with genome sequencing in a trio way versus the genome sequencing in a solo way, to identify the find a final diagnosis for patient presenting neurodevelopmental disorders with developmental abnormalities and without an evident diagnosis after chromosome microarray and\u002For exome sequencing analysis.\n\nTo successfully carry out the ATOMICS study, investigators plan to recruit patient in a protocol considered with minimal risk and minimal constraints, to compare Ribonucleic Acid-seq performed on fibroblasts, in addition to genome sequencing in a solo or a trio manner, to trio genome sequencing alone, with the final objective in mind to obtain an etiology diagnostic for a patient presenting with neurodevelopmental disorders and development abnormalities.",[573],"Neurodevelopmental Disorders and Developmental Abnormalities",{"date":411,"type":37},{"date":576,"type":37},"2025-11-04",{"date":578,"type":21},"2028-05-04",{"name":43,"class":44},{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":22,"phases":590,"briefSummary":591,"conditions":592,"keywords":598,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":610,"locationsCount":611},"100531111","phase-3-rivaroxaban-versus-low-molecular-weight-heparin-in-patients-with-lower-limb-trauma-requiring-brace-or-casting-100531111","NCT06195540","RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST : RIVAroxaban Versus Low-molecular Weight Heparinin Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST","Inclusion Criteria:\n\n* Patient aged 18 or over ;\n* Consultation in an emergency department of a participating centre;\n* Trauma to the lower limb requiring rigid or semi-rigid orthopaedic immobilisation;\n* Expected duration of orthopaedic immobilisation of at least 2 weeks;\n* TRiP(cast) score ≥ 7 ;\n* Patient affiliated to or benefiting from a social security scheme;\n* Patient with prior informed consent.\n\nExclusion Criteria:\n\n* Patient that have to be hospitalized after emergency department for other reason than lower limb trauma\n* Active bleeding or high risk of bleeding,\n* Known contraindication to rivaroxaban or LMWH;\n* Taking any anticoagulant or antiplatelet agent before the trauma (only antithrombotic authorised: aspirin \\\u003C 325mg\u002Fd);\n* Pregnant or breastfeeding woman;\n* Any factor making 3-month follow-up impossible; 6. Patient subject to a legal protection measure, Imprisonment 7. Participation in any interventional study which modifies patient care or could influence study evaluation criteria",{"count":589,"type":21},1424,[300],"Lower limb trauma requiring immobilization is a very frequent condition that is associated with an increased risk of developing venous thromboembolism (VTE). The TRiP(cast) score has been developed to provide individual VTE risk stratification and help in thromboprophylactic anticoagulation decision. The recent CASTING study had confirmed that patients with a TRiP(cast) score \\\u003C7 have a very low risk of VTE and could be safely manage without prophylactic treatment. Conversely, patients with a score ≥ 7 have a high-risk of VTE and require a prophylactic anticoagulant treatment. Low molecular weight heparins (LMWH) have been shown to be effective in this indication. However, in the CASTING study, the 3-month symptomatic VTE rate was 2.6% in this subgroup despite LMWH prophylactic treatment. This result suggests that LMWH are not sufficiently effective in this particular subgroup of high-risk patients. Direct oral anticoagulants, and in particular rivaroxaban, may be an effective and safe alternative to LMWH. In the PRONOMOS study, comparing LMWH with rivaroxaban in patients who had undergone non-major lower limb surgery, the relative risk of symptomatic VTE was 0.25 (95% CI = 0.09 - 0.75) in favor of rivaroxaban 10mg. No significant increase in bleeding was found. In addition, as LMWH treatment requires subcutaneous daily injections, the use of rivaroxaban may positively impact patients' quality of life as well as being effective in medico-economic terms.\n\nThe aims of this study are to demonstrate that rivaroxaban is at least as effective, easier to use and more efficient than LMWH in patients with trauma to the lower limb requiring immobilisation and deemed to be at risk of venous thromboembolism (TRiP(cast) score ≥ 7). High-risk patients are randomized to receive either rivaroxaban or LMWH. They are followed up at 45 days and 90 days to assess the occurrence of thrombotic events or bleeding, as well as their satisfaction with the treatment received.",[327,593,594,595,596,597],"Deep Vein Thrombosis","Pulmonary Embolism","Lower Limb Trauma","Thromboprophylaxis","Immobilisation",[599,600,601,602,603,604],"Emergency department","direct oral anticoagulant","rivaroxaban","Low-Molecular-weight heparin","randomized control trial","Prevent VTE","2026-06-22",{"date":465,"type":37},{"date":608,"type":37},"2024-07-19",{"date":119,"type":21},{"name":43,"class":44},37,{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":22,"phases":622,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":635,"locationsCount":121},"100595132","new-care-pathway-using-automated-dynamic-laximetry-100595132","NCT07028476","New Care Pathway Using Automated Dynamic Laximetry","NPS-LDA - New Care Pathway Using Automated Dynamic Laximetry","NPS-LDA","Inclusion Criteria:\n\n* Patient admitted to an emergency department participating in the study\n* Age ≥ 18 years\n* Consulted following knee trauma and whose clinical examination leads to the suspicion of a partial or complete ACL lesion without bone fracture (supporting radiograph).\n* Signed consent to participate in the study\n* Affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Contraindication to MRI (pacemaker fitted before 2010) or LDA;\n* Indication for emergency or semi-emergency trauma surgery (within 3 weeks: suspected unstable meniscal lesion, fracture, etc.).\n* Impossible follow-up or patient's refusal of follow-up in the investigating center's sports medicine department;\n* Poor understanding of the French language\n* Pregnant (known or suspected pregnancy), breast-feeding or parturient woman;\n* Person deprived of liberty by judicial or administrative decision;\n* Person under compulsory psychiatric care;\n* Person subject to a legal protection measure\n* Person unable to give consent",{"count":621,"type":21},80,[24],"Today, in the event of a knee sprain with suspected cruciate ligament damage, magnetic resonance imaging (MRI) is generally prescribed to confirm or refute the diagnosis and assess its severity. Once the MRI has been performed, the patient's care is organized by the doctor of his or her choice, depending on the diagnosis.\n\nPrevious studies have shown that Automated Dynamic Laximetry (ADL) performs identically to MRI in helping to diagnose a knee sprain as a complementary examination and in assessing its severity. Performing LDA at the start of the patient's care pathway, i.e. immediately after the emergency room visit for a suspected severe sprain, could bring significant benefits by shortening the diagnostic confirmation time and consequently the immobilization period, and by reducing the cost of care compared with the conventional MRI-based care pathway. The new LDA-based care pathway would enable MRI to be reserved for very specific cases, such as the scheduling of surgery for suspected meniscus or osteochondral lesions, as currently recommended by the HAS.",[625,626,627,628],"Knee Sprain","Automated Dynamic Laximetry (ADL)","Care Pathway","MRI","2026-06-17",{"date":631,"type":37},"2026-06-18",{"date":633,"type":37},"2026-03-10",{"date":213,"type":21},{"name":43,"class":44},""]